All In Biotech

Drug Trial Radar · NCT07859111

YJ001 Spray for Diabetic Peripheral Neuropathic Pain

Multicenter, Randomized, Double-blind, Double Simulation, Positive Drug and Placebo Parallel Control Phase III Clinical Trial And Open-label Extension Trial of YJ001 for Spray Use the Treatment of Diabetic Peripheral Neuropathic Pain

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Aug 3, 2026

Primary completion

Aug 30, 2028

Study completion Aug 30, 2028

Sponsor

Sponsor type
Industry
First posted
Oct 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if YJ001 Spray works to treat diabetic patients with Diabetic Peripheral Neuropathic Pain..It will also learn about the safety of drug YJ001 Spray.This trial is divided into two parts. The first part of the trial is designed as a randomized, double-blind, double-dummy, parallel-controlled, multi-center clinical trial with positive reference product and placebo; the second part is designed as a single-arm, open-label, multi-center clinical trial.In the first part, the trial was divided into the test group, the positive control group, and the placebo group. In the first part,The experimental group received YJ001 spray + clobazam besylate capsule placebo, the positive control group received YJ001 spray placebo + clobazam besylate capsule, and the placebo group received YJ001 spray placebo + clobazam besylate capsule placebo. In the second part, all participants were treated with the investigational product, and 30 trial participants underwent PK blood sample collection according to the protocol. Part I of the trial : To evaluate the efficacy and safety of YJ001 spray in treating diabetic peripheral neuropathic pain. Part 2 of the trial: Evaluate the long-term efficacy and the pharmacokinetic characteristics of YJ001 spray in treating dia betic peripheral neuropathic pain at the clinically recommended dosage. Participants will: Apply spray topically to both feet twice daily, with six sprays per foot at each administration. Visit the clinic once every 1 or 2 or 4 weeks for checkups and tests Complete a study diary daily to record pain intensity, sleep interference, study-drug administration, and spray-related respiratory irritation.

Conditions

  • Diabetic Peripheral Neuropathic Pain (DPNP)

Interventions

  • YJ001 spray simulantDrug

    spray:0 mg/dose, once in the morning and once in the evening, 6 sprays per foot each time.

  • YJ001 sprayDrug

    spray:480 mg/dose, once in the morning and once in the evening, 6 sprays per foot each time.

  • Crisugabalin Besilate CapsulesDrug

    capsule:20mg per dose, twice a day

  • Crisugabalin Besilate Capsules simulantDrug

    0mg per dose, twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Average Daily Pain Score (ADPS)Time frame: Week 12
  2. Number of participants with clinically significant changes in safety parameters from baselineTime frame: week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical Institution

    Beijing, Haidian District, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.